In our analysis we explored the impact of HLA-DPB1 mismatches on GRFS, a composite endpoint now increasingly used for assessing the success of HSCT, as it simultaneously measures the proportion of patients free from disease and GvHD (33). This evidence concerns the gene HLA-DPB1 and graft versus host disease.